A report from the Cross-Disorder Group of the Psychiatric Genomic Consortium, after performing a GWAS for the five disorders—autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), BD, major depressive disorder, and schizophrenia (SCH)—in 33,332 cases and 27,888 controls, showed that single-nucleotide polymorphisms (SNPs) at four loci (regions on chromosomes 3p21 and 10q24, SNPs within CACNA1C and CACNB2) attained genome-wide significance for several of these disorders7. The gene discussed is CACNB2; the disease is attention deficit-hyperactivity disorder.